Velodyne Lidar Demonstrates How Advanced Lidar Technology Can Improve Pedestrian Safety
18.3.2021 13:48:00 EET | Business Wire | Press release
While overall driving was down 13 percent in miles driven last year due to the COVID-19 pandemic, motor vehicle deaths were up 8 percent in the United States, reported the National Safety Council. Velodyne Lidar, Inc. (Nasdaq: VLDR, VLDRW) today showed how with lidar technology, Pedestrian Automated Emergency Braking (PAEB) systems can be significantly improved, with the potential to save thousands of lives annually.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210318005164/en/
Velodyne released a new video that showcases how its affordable lidar-based PAEB solution delivers superior performance in all conditions, a decisive advantage over radar+camera-based systems. This is especially critical at night with the National Highway Traffic Safety Administration (NHTSA) reporting 80 percent of pedestrian fatalities occur during dark lighting conditions.
The Velodyne video presents striking test results where a highly-rated PAEB system using radar+camera-based technology failed in all six nighttime scenarios while the Velodyne PAEB solution avoided a crash in every situation. These results support independent testing by NHTSA and the American Automobile Association (AAA) to confirm whether PAEB systems which use radar+camera-based technology adequately protect pedestrians in dark conditions.
The Velodyne PAEB solution combines proprietary software, called Vella, with Velodyne’s lidar sensors. The sensors can be easily embedded in a variety of places around a vehicle, including behind the windshield. Vella software interprets lidar data to avoid and mitigate crashes with moving and static objects. Through predictive collision monitoring, Vella compares a vehicle’s trajectory with other road users and objects to identify and avoid imminent crash scenarios.
Velodyne is sharing the company’s PAEB test methodology and findings with NHTSA and other auto safety leaders. NHTSA has a pending proposal to update its New Car Assessment Program (NCAP), adding advanced driver assistance system (ADAS) capabilities, including PAEB, to the NCAP. Velodyne is very supportive of NHTSA’s NCAP plan to keep pace with evolving safety technologies and providing much-needed information to consumers, and looks forward to NHTSA leadership completing the review of this measure and moving ahead with its request for comment.
“Our PAEB testing initiative clearly demonstrates the imperative for regulatory agencies and testing organizations to include nighttime conditions in their PAEB assessment protocols,” said Anand Gopalan, CEO, Velodyne Lidar. “Everyone, particularly automakers and drivers will expect that ADAS, such as PAEB, perform effectively in a wide variety of lighting situations, particularly at night when the most pedestrian fatalities occur. We believe Velodyne’s lidar data and Vella processing software have shown to be effective and ready for implementation, with the potential to save the lives of thousands of pedestrians annually.”
Velodyne PAEB Testing Methodology
The Velodyne PAEB tests were conducted at nighttime, without streetlights, at less than 1 lux ambient lighting in an independent testing facility. The two vehicles in the test were driving at 30 mph on a straight track. The test vehicles each had their low beam headlights on during the trials. Stationary child and adult pedestrian dummy targets were used, compatible with testing protocols prescribed by Insurance Institute for Highway Safety (IIHS) and Euro NCAP.
Six scenarios were evaluated with both vehicles tested in each scenario five times or until the vehicle collided with the target three times, to minimize damage to the targets and vehicles. The scenarios in which vehicles were evaluated were crossing adult at 50 percent overlap (at the center of the test vehicle’s width); crossing adult at 25 percent overlap; crossing child at 50 percent overlap; crossing child at 25 percent, adult at 75 percent, 10 feet behind child; crossing adult at driver-side corner and fallen adult at 50 percent overlap.
The vehicle with Velodyne’s lidar-based PAEB system, equipped with one Velarray lidar sensor, successfully stopped in time to avoid a crash five out of five times for every scenario tested. The vehicle equipped with a PAEB system using radar+camera-based technology failed in every scenario tested.
Additional details on the Velodyne PAEB testing can be found in a white paper, called “Improving Pedestrian Automatic Emergency Braking (PAEB) in Dark, Nighttime Conditions.”
About Velodyne Lidar
Velodyne Lidar (Nasdaq: VLDR, VLDRW) ushered in a new era of autonomous technology with the invention of real-time surround view lidar sensors. Velodyne is the first public pure-play lidar company and is known worldwide for its broad portfolio of breakthrough lidar technologies. Velodyne’s revolutionary sensor and software solutions provide flexibility, quality and performance to meet the needs of a wide range of industries, including autonomous vehicles, advanced driver assistance systems (ADAS), robotics, unmanned aerial vehicles (UAV), smart cities and security. Through continuous innovation, Velodyne strives to transform lives and communities by advancing safer mobility for all. For more information, visit www.velodynelidar.com.
Forward Looking Statements
This press release contains "forward looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995 including, without limitation, all statements other than historical fact and include, without limitation, statements regarding Velodyne’s target markets, new products, development efforts, competition. When used in this press release, the words "estimates," "projected," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," “can,” "should," "future," "propose" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Velodyne's control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, that may affect actual results or outcomes include changes in laws, regulations or judicial interpretations to which Velodyne or its customers are subject; the uncertain impact of the COVID-19 pandemic on Velodyne's and its customers' businesses; Velodyne's ability to manage growth; Velodyne's ability to execute its business plan; uncertainties related to the ability of Velodyne's customers to commercialize their products and the ultimate market acceptance of these products; uncertainties related to Velodyne's estimates of the size of the markets for its products; uncertainties regarding government regulation and adoption of lidar for pedestrian safety, traffic congestion and smart city applications; the rate and degree of market acceptance of Velodyne's products; the success of other competing lidar and sensor-related products and services that exist or may become available; Velodyne's ability to identify and integrate acquisitions; uncertainties related to Velodyne's current litigation and potential litigation involving Velodyne or the validity or enforceability of Velodyne's intellectual property; and general economic and market conditions impacting demand for Velodyne's products and services. Velodyne undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210318005164/en/
Contact information
Investor Relations
Andrew Hamer
Chief Financial Officer
InvestorRelations@velodyne.com
Media
Landis Communications Inc.
Sean Dowdall
(415) 286-7121
velodyne@landispr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 08:30:00 EEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
